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Abstract
Animal models of chronic pain are widely used to investigate basic mechanisms of chronic pain and to evaluate
potential novel drugs for treating chronic pain. Among the different criteria used to measure chronic pain,
behavioral responses are commonly used as the end point measurements. However, not all chronic pain
conditions can be easily measured by behavioral responses such as the headache, phantom pain and pain related
to spinal cord injury. Here I propose that cortical indexes, that indicate neuronal plastic changes in pain-related
cortical areas, can be used as endpoint measurements for chronic pain. Such cortical indexes are not only useful
for those chronic pain conditions where a suitable animal model is lacking, but also serve as additional screening
methods for potential drugs to treat chronic pain in humans. These cortical indexes are activity-dependent
immediate early genes, electrophysiological identified plastic changes and biochemical assays of signaling proteins.
It can be used to evaluate novel analgesic compounds that may act at peripheral or spinal sites. I hope that these
new cortical endpoint measurements will facilitate our search for new, and more effective, pain medicines, and
help to reduce false lead drug targets.
Introduction
Pain has at least two different major forms: acute pain
that is short-lasting, and often serves as protective and
learning signals. It is also called physiological pain in
part due to its important physiological functions. The
second form is chronic pain that is long-lasting pain
caused by injury to tissue or nerve systems. Although it
also informs animal or patients the location of the
injured area, the long-term component of chronic pain
is not physiological critical, and it causes cognitive
impairment, emotional sufferings, loss of sleep and
mood disorders. Thus, it is also called pathological pain.
Due to the lack of understanding of cellular and mole-
cular mechanisms of pain mechanisms; the black box
experimental approach for studying pain has been
widely used by basic researchers and drug developers
(Figure 1). Among many different experimental
approaches, behavioral reflexes in response to noxious
stimuli, or allodynic stimulation after tissue or nerve
i n j u r ya r ew i d e l yu s e df o rt h ei nvestigation of potential
analgesic effects of new drugs, and often proposed as
the endpoint of pain indexes. The use of neurobiological
approaches is mainly targeted for the investigation of
basic mechanisms of pain transmission, modulation and
plasticity; and has not been used or proposed as the
endpoint measurement of pain.
The progress made in human brain imaging has sig-
nificantly improved our understanding of chronic pain.
Brain imaging in conscious humans allow us to evaluate
roles of various cortical areas in pain, and brain activa-
tion by painful stimuli can be evaluated and compared
with patient’s psychological reports of pain and emo-
tional feelings [1]. Recently such techniques have also
been successfully used to measure psychological pain or
empathy of pain [2,3]. And the measurement of reflexive
responses in such human studies is not needed. Can we
achieve similar aims in animal studies of chronic pain?
In this review, I would like to propose that neurobiolo-
gical indexes obtained from pain-related cortical neu-
rons can be used as new cortical endpoints of pain
measurements in animal models of chronic pain. The
use of such new endpoints will allow us to study certain
types of chronic pain that is difficult to be investigated
in animal models due to the lack of motor responses.
They are: headaches, seizure induced pain, phantom
pain, spinal injury induced pain and chronic back pain.
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based measurements of chronic pain in animal models,
and could be used as better assays for screening poten-
tial new drugs for treating chronic pain. It is important
to point out that I am not proposing to use those new
endpoints to replace the existing behavioral models of
chronic pain such as measuring threshold in hyperalge-
sia and behavioral responses to allodynic stimulation in
chronic pain conditions. The combination of these corti-
cal and behavioral endpoints can provide excellent pain
endpoint measurements with solid basic neurobiological
mechanisms. The new cortical endpoints can be also
used effectively for basic investigation of pain mechan-
isms at peripheral tissue/nerve, spinal cord, and subcor-
tical areas.
Problems that we are facing: drug discovery and
translational medical researches
While animal models of chronic pain have greatly
facilitated our understanding of basic pain mechan-
isms, there are still many major problems that cannot
be solved using animal behavioral models. Many forms
of clinical pain cannot be mimicked in animal models.
For example, it is very difficult to measure ‘phantom’
pain in amputated animals; and it is impossible to
measure nociceptive withdrawal responses in animals
with spinal cord injuries. Mimicking headaches and
chronic back pain in animals is also proved to be
extremely difficult, since there is not a clear behavioral
motor response related to such pain that can be mea-
sured. Furthermore, even in many pain conditions that
the measurement in animal behavioral responses to
pain are possible, the pain index is often affected by
unwanted side effects on motor or pre-motor func-
tions. For example, in case of animal models of che-
motherapy induced neuropathic pain, the same
chemicals also caused injury to motor neurons/nerves.
Defects in motor functions directly affect the measure-
ment of nociceptive responses, if only motor responses
are used as pain index such as withdrawal thresholds
or latencies. Finally, most of potential analgesic drugs
also act on motor neurons non-selectively. There is
great need to develop additional non-behavioral mea-
surements for chronic pain.
Figure 1 Black box experimental approaches for the investigation of pain mechanism. To investigate acute or physiological pain in
animals, sensory noxious stimuli are typically used to induce behavioral motor responses in awake or lightly-anesthetized animals. For noxious
stimuli, thermal or mechanical stimuli are commonly used. For motor responses, withdrawal reflexes or escaping responses are measured. In
some cases, electrodes are used to measure muscle activities (e.g., visceral pain responses). The manipulation or pharmacological agents are
introduced to the central nervous systems at different levels (i.e., spinal cord by intrathecal catheters; supraspinal areas by microinjections).
Reduction or inhibition of behavioral motor responses is used as the endpoint of pain responses. Complete inhibition of motor responses such
as tail-flick or hindpaw withdrawal due to the manipulation in the ‘black box’ is treated as 100% analgesic or antinociceptive. Similar
experimental approaches are often used for studying chronic pain as well in various animal models.
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roles of cortex in chronic pain
Unlike animal experiments, human brain imaging using
functional magnetic resonance imaging (fMRI) and posi-
tron emission tomography (PET) have greatly increased
basic neuronal mechanisms for chronic pain, especially
at the brain areas. The imaging in conscious patients
provides the unique opportunity to investigate if any
abnormal neuronal activities may be related to chronic
pain in patients [4-7]. Progress made in human imaging
of chronic pain is very impressive. Between year 2000
and now, there is an average of 300 papers published
per year when the searching key word ‘brain imaging’,
‘pain’ and ‘human’ were used. To deal with this huge
amount of imaging data, some mega-analyses have been
performed recently [5,8]. Among different cortical
regions, there are five major cortical areas that are con-
sistently responding to pain. They are: anterior cingulate
cortex (ACC), insular cortex (IC), primary somatosen-
sory cortex (S1), secondary somatosensory cortex (S2)
and prefrontal cortex (PFC) (Table 1). Among them, the
ACC is found to be the most reliable area to be acti-
vated by different noxious or painful stimuli. In addition
to the ACC, the IC is also commonly activated by differ-
ent painful stimuli [9,10,8] for review].
Classical pain endpoints —behavioral models of
chronic pain
In basic research area, behavioral studies have been
commonly used for measuring endpoint of chronic pain.
Most of pharmaceutical drug discovery is focused on
two major areas: target proteins and the behavioral
endpoints, at least to my knowledge. The behavioral
evaluations in animal models of chronic pain are used
as the end point for preclinical studies. Despite many
limitations of behavioral tests (any pre-motor or motor
side effects of drugs or gene mutant can easily affect
behavioral responses in freely moving conditions), these
‘analgesic’ indexes are commonly used, because it is eco-
nomic, fast, and easily understood by laypersons such as
private investors.
The failure to provide consistent non-behavioral end-
points for chronic pain also complicates drug discovery;
and too many potential lead drugs work well in animal
models of chronic pain. In any pain-related conferences
held in recent years, you often hear much more positive
drug target proteins than negative ones. Furthermore,
the failure to require solid basic scientific evidence by
the drug regulator encourages the cheap- and short-cut
experimental approaches used by private investors and
drug developers. Furthermore, many of these ‘analgesic
drugs’ failed to be translated into clinical drugs, in part
due to the fact that only behavioral endpoints were used
in many of these preclinical studies.
Clinical image studies of those unstudied chronic
pain
It is easy to tell humans are different from animals in
term of reporting pain, although humans complain
about pain for just for pain. Previous studies reported
that animal vocalization activities may be used to mea-
sure pain or especially spontaneous pain [11-13]. How-
ever, these indexes prove to be difficult to be used, since
animals also generate vocalization activities under other
Table 1 Cortical areas that are implicated in chronic pain conditions by human brain imaging fMRI that are difficult to
be investigated by traditional animal pain models
Cortical area Clinical pain conditions Major discovery
ACC Migraine/headache
Phantom pain
SCI induced pain
Chronic back pain
Altered excitatory transmission
Related to increased imaged activity
Increased activity with imaged pain
Increased activity
IC Migraine/headache
Chronic back pain
Hypothically induced pain
Altered excitatory transmission
Increased imaged activity
Increased imaged activity
PFC Migraine/headache
Phantom pain
SCI induced pain
Chronic back pain
Hypothically induced pain
Altered brain metabolism
Related to increased imaged activity
Increased activity with imaged pain
Correlated with spontaneous pain; reduced gray matter density
Increased imaged activity
S1, S2 Migraine/headache
Phantom pain
SCI induced pain
Altered sensory transmission
Correlation of cortical reorganization
Correlated with cortical reorganization
Abbreviations:
ACC: anterior cingulate cortex.
IC: insular cortex.
PFC: prefrontal cortex.
S1: primary somatosensory cortex.
S2: Secondary somatosensory cortex.
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Recent human studies using brain imaging have pro-
vided key evidence for the involvement of central ner-
vous systems in several chronic pain conditions that
cannot be mimicked in animal models. These include
headache, phantom pain, back pain, pain related to
spinal cord injury, and patient with functional bowel
disorder [14,15]. For example, Willoch et al (2000)
reported that in human amputees the activity increased
in the ACC and posterior cingulate as well as thalamus
is correlated with pain reported in phantom limb, while
the activity in the supplementary motor cortex and pri-
mary sensorimotor cortex is related to the phantom
limb movement [16]. Apkarian et al (2004) reported
that chronic back pain is associated with decreased pre-
frontal and thalamic gray matter density [6], and altered
neural activity in the PFC [17].
Recent studies of neural correlates of social exclusion
by neuroimaging study found that the ACC is more
active during exclusion rather than during inclusion [2],
suggesting that psychological rejection in social exclu-
sion also triggers pain-related cortical areas. In case of
patients with spinal cord injury, it has been reported
that the magnitude of activation in the perigenual ACC
and right dorsolateral PFC was significantly correlated
with absolute increases in pain intensity triggered by
movement imagery [18]. Similar findings have also been
reported in patients with chronic low back pain [19].
These human studies are in consistent with previous
anatomic studies in animals that somatosensory cortex
reorganized itself after spinal cord injury [20]. Cumula-
tive human studies data consistently indicate that corti-
cal activity plays an important role in chronic pain. In
many cases, changes in cortical activities without any
peripheral stimuli (including spontaneous pain condi-
tions) are sufficient to produce pain in patients.
A proposal for using cortical plasticity as the
endpoint measurements for chronic pain
Here I would like to propose the use of cortical plasti-
city as an endpoint measurement for chronic pain,
including biochemical, electrophysiological and imaging
measurements (Table 2). Such non-behavioral measure-
ments can also be used to measure cortical responses in
animal models that behavioral tests are applicable such
as animal models of inflammatory and neuropathic pain.
In cases of types of pain where behavioral measurement
are impossible, these cortical markers can be used to
evaluate pain. Cortical long-term changes can be used
as markers for measuring drugs’ effects in animal mod-
els of chronic pain. Drugs that act at the level of periph-
ery or spinal cord may reduce or inhibit such activation
in the cortex if they are potential analgesic for chronic
pain.
1. Activity-dependent immediate early gene (IEG)
Activity-dependent immediate early genes are known to
be activated by neuronal activity in the central nervous
system. Peripheral noxious stimuli or injury triggered
activation of c-Fos and phosphorylation of cAMP
response element binding protein (pCREB) in the spinal
cord dorsal horn neurons [21,8]. Such activation in the
spinal cord dorsal horn neurons can be inhibited or
blocked by drugs or inhibited behavioral sensitization. It
is believed that these activity-activated immediate early
genes may contribute to long-term plastic changes in
spinal sensory synapses, and thus contribute to beha-
vioral sensitization. It is expected that analgesics that
acts at the level of spinal cord or periphery for the treat-
ment of chronic pain should at least partially reduce
activation of IEGs triggered by the injury.
Activation of IEGs is not limited at the spinal cord
level. Along the somatosensory pathways, activation of
IEGS have also been reported in the thalamus, and
related cortical areas. Among several pain-related
Table 2 Proposed cortical markers for measuring pain
endpoints in chronic pain
Category Measure index
Immediate early gene Activation of c-Fos; Egr1; pCREB
Cortical potentiation Enhanced AMPA receptor mediated EPSCs
Presynaptic
enhancement
Paired-pulse
facilitation (PPF)
PPF ratio
mEPSCs Frequency
Amplitude
Postsynaptic
potentiation
AMPA receptor Inward rectification
NMDA NR2B
receptor
Enhanced NR2B sensitive EPSCs
PKMζ inhibition More sensitive to ZIP inhibition
Biochemistry
AMPA receptor
GluR1
Increased membrane bind AMPA receptor
p-AMPA receptor Increased phosphorylation at PKA site
PKMζ Enhanced pPKMζ
In vivo field LTP Injury induced LTP
Structural changes Outgrow of neuronal dendrites and increased
spine density
Brain imaging & in vivo
whole-cell
Increased spike responses to non-noxious
stimuli
Enhanced cortical activities before and/or after
peripheral stimuli
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after the injury has been reported in the ACC and IC.
Using c-Fos, NGFI-A (also called Egr1, zif268), and
pCREB, neurons in the ACC are known to be activated
by peripheral noxious stimuli, injury or amputation
[22-24]. Wei et al (1999) reported that digit amputations
in adult rats triggered rapid activation of Fos, Egr1 and
CREB in the ACC neurons, especially pyramidal cells
located in the layer II-III (Figure 2). Activation of IEGs
is bilateral. It persists for two days [23]. Similar activa-
tion of IEGs in the ACC has been reported after tissue
inflammation, nerve injury and visceral pain [8].
Using gene knockout mice, it has been shown that the
amount of IEG activation may be related to behavioral
pain phenotypes. In adenylyl cyclase subtype 1 (AC1) or
AC1 and AC8 knockout mice, it has been shown that
chronic inflammatory pain and neuropathic pain were
significantly reduced. Consistently, pCREB immunoreac-
tivity induced by hindpaw inflammation was also
reduced in AC1, AC8, or AC1&8 double knockout
(DKO) mice. Activation of IEGs is also noted in other
cortical areas such as IC [25]. Similar to the ACC, the
amount of gene expression is likely also related to beha-
vioral pain phenotypes. Interestingly, fear condition, a
form of emotional learning, also triggered IEGs in corti-
cal neurons [26]. Activation of Ca2+-calmodulin-depen-
dent protein kinase IV (CaMKIV) is functionally
important for activation of IEGs as well as behavioral
memory [26]; indicating that different intracellular sig-
naling pathways may be involved in mediating fear and
chronic pain.
In addition to assay baseline neuronal changes after
the injury, some of these makers can be also used to
evaluate allodynic responses in animals with the injury.
In animals at two weeks after the injury, most of IEGs
activities return to baseline level in the ACC. Non-nox-
ious stimuli that usually did not induce any obvious
behavioral response and gene expression in the ACC
triggered remarkable IEG activation within the ACC
[see [27]] (Figure 3). Similar studies in adult rats with
nerve injury have reported that mild noxious stimuli
triggered significant activation of phosphorylated-c-Jun
activity in the cingulate cortex [28].
2. Cortical potentiation
Glutamate is the major excitatory fast transmitter in the
cortical areas including the ACC [29]. Postsynaptic
synaptic responses are mainly mediated by postsynaptic
glutamate a-amino-3-hydroxy-5-methyl-4-isoxazole-pro-
pionate (AMPA) receptors with a small portion of cur-
rents are mediated by kainate (KA) receptors [29]. It has
been proposed that excitatory synapses in the ACC
undergo long-term potentiation (LTP) after peripheral
injury [21,8]. Considering ACC neurons show wide
spread activation to peripheral injury [22], it is much
easier to detect changes in excitatory synaptic transmis-
sion in the ACC area. To explore whether there is any
change in basal synaptic transmission within the ACC
after nerve injury, AMPA receptor-mediated EPSCs in
pyramidal neurons in the layer II/III of the ACC are
measured in mice with peripheral nerve ligation [30].
Recorded neurons were identified as pyramidal neurons
based on their ability to show spike frequency adapta-
tion in response to the prolonged depolarizing-current
injection [31-33]. Indeed, we found that input (stimula-
tion intensity)-output (EPSC amplitude) curve of AMPA
receptor-mediated current was significantly shifted to
the left after peripheral nerve injury, compared with that
in control group (Figure 4). These results suggest that
excitatory synaptic transmission was increased in the
ACC after peripheral nerve injury.
Figure 2 Potentiation of IEG expression in the ACC after the
amputation. Photomicrographs showing expression of c-Fos and
NGFI-A (A) and phosphorylation of CREB (B) in the coronal ACC
sections from sham animals (Ctrl) and animals at different times
after the amputation of the unilateral hindpaw third digit. Scale
bars, 500 μm. The numbers of c-Fos-, NGFI-A-, and pCREB-
immunoreactive cells increased bilaterally after the amputation
(from Reference 18).
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models of inflammation induced by complete Freund’s
adjuvant (CFA) [34]. CFA injection caused significant
potentiation of the input-output relationship of the glu-
tamate mediated excitatory transmission in the ACC of
adult mice. Similar changes were found in animals with
inflammation in rats (CFA model). Bie et al (2010)
reported that CFA inflammation in rats triggered
increased AMPA receptor mediated responses in ACC
neurons with observed leftward shift of the input-out
curves [35].
3. Presynaptic enhancement of glutamate release
Paired-pulse facilitation (PPF) is a transient form of
plasticity commonly used as a measure of presynaptic
function, in which the response to the second stimulus
is enhanced as a result of residual calcium in the presy-
naptic terminal after the first stimulus [34,36]. In
Figure 3 Enhanced Erk activation in the ACC after tissue and nerve injury. A. Immunohistochemical staining for phosphorylation of Erk
illustrated time course-dependent activation of Erk in layer II neurons of the contralateral ACC after unilateral hindpaw injection of formalin (5%,
50 μl, n = 4-5 rats for each time point). B. The P-Erk expression in the layer II ACC neurons and their main apical dendrites (arrows) was
increased at 2 weeks after the amputation of the unilateral hindpaw third digit (n = 5), compared to sham animals (n = 3). C. Mechanical
stimulation by brushing hindpaw of digit amputation induced P-Erk expression in more number of layer II ACC neurons and the more distinctive
apical dendrites at 2 weeks after the amputation (n = 5), compared to that in rats with amputation alone. There was not P-Erk activation in the
ACC in normal animals after the brushing (n = 3). Left and middle columns: low power of the coronal ACC sections. Scale bar = 50 μm; Right
column: enlarged layer II regions corresponding to the small rectangle areas in the middle column, respectively. Scale bar = 25 μm (from
Reference 22).
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intervals of 35, 50, 75, 100, and 150 ms. After nerve
ligation, there was a significant reduction in PPF in
ACC neurons compared with those from control mice.
The changes in PPF ratio is selective for neurons in
layer II/III, no obvious changes were detected in deeper
neurons in the ACC. These results indicate that presy-
naptic enhancement of the excitatory synaptic transmis-
sion selectively occurs in the layer II/III of the ACC
after nerve injury (Figure 4). Similar changes in PPF
ratio are found in ACC neurons of animals with CFA
inflammation [33], indicating that presynaptic enhance-
ment of glutamate release is also shared by peripheral
inflammation.
In addition to the use of PPF in the ACC after periph-
eral nerve injury, AMPA receptor-mediated miniature
excitatory postsynaptic currents (mEPSCs) in ACC neu-
rons in the presence of 0.5 μM tetrodotoxin (TTX) were
also found to be affected. After peripheral nerve injury,
there was an obvious increase of mEPSC frequency in
ACC neurons compared with that of control group.
Furthermore, there was significant difference in the
amplitude of mEPSCs between the two groups, indicat-
ing postsynaptic changes in AMPA receptor mediated
responses (see below). By contrast, no significant change
in mEPSCs amplitudes is detected in animal model of
inflammation [34]. However, this does not completely
rule out possible postsynaptic changes that may contri-
bute to inflammatory pain in the ACC.
I nar e c e n ts t u d y ,t h eu s eo fc - F o st r a n s g e n i cm i c ea l l o w s
one to selectively record pain-trigger cortical cells [37].
The combination of c-Fos transgenic mice and PPF can
help to detect selective changes in pain-activated synapses.
4. Postsynaptic glutamate mediated responses
AMPA receptor
AMPA receptors without GluR2 are Ca
2+ permeable and
inwardly rectifying [38-40]. Inward rectification occurs
by voltage-dependent blockade by polyamines [41]. To
identify whether there are inwardly rectifying properties
of AMPA receptors as a result of an alteration of their
subunit composition in ACC neurons after nerve injury,
AMPA receptor-mediated EPSCs were induced at the
holding potentials of -65, -5, and +35 mV in ACC neu-
rons. We found that there was significant difference in
the rectification of AMPA receptor-mediated transmis-
sion in the ACC between control and nerve-ligated mice
[36]. Consistently, when the mean current-voltage (I-V)
relationship was plotted, less inward currents were
found in ACC neurons from mice with nerve injury
compared with control mice [36]. These results demon-
strate that AMPA receptor in ACC neurons has an
inward rectification property in neuropathic pain.
Similar rectification of the AMPA receptor mediated
responses in ACC neurons of rats has been reported
after peripheral inflammation with hindpaw CFA injec-
tion [35].
Postsynaptic NMDA NR2B receptor
Evidence for the involvement of cortical NMDA NR2B
receptor in chronic pain first comes from the NMDA
NB2B forebrain overexpressed ‘smart’ mice [42,43]. In
this transgenic mouse with selective forebrain NMDA
NB2B overexpression, inflammatory pain and allodynia
were significantly enhanced without any significant
effect on acute pain. Subsequent studies demonstrated
that peripheral inflammation with CFA injection trig-
gered long-lasting increases in the expression of NMDA
NR2B receptor proteins in the ACC [44,45]. The
Figure 4 Increased synaptic transmission in layer II/III in the
ACC after peripheral nerve ligation. A, Synaptic input-output
curves in slices from control (n = 6 neurons) and nerve-ligated (n =
7 neurons) mice. *p < 0.05 and **p < 0.01 compared with those of
control group. Open circles, Neurons from control mice; filled circles,
neurons from mice with nerve ligation. B, Representative traces with
an interval of 50 ms recorded in layer II/III of the ACC. Paired-pulse
ratio (the ratio of EPSC2/EPSC1) was recorded at intervals of 35, 50,
75, 100, and 150 ms from control and nerve-ligated mice. Open
circles, Neurons from control mice (n = 17 neurons); filled circles,
neurons from mice with nerve ligation (n = 19 neurons). *p < 0.05;
**p < 0.01; ***p < 0.001. C, PPF in layer V of the ACC from control
and nerve-ligated mice. Open circles, Neurons from control mice (n
= 9 neurons); filled circles, neurons from mice with nerve ligation (n
= 15 neurons). D, PPF in motor cortex neurons from control and
nerve-ligated mice. Open circles, Neurons from control mice (n = 5
neurons); filled circles, neurons from mice with nerve ligation (n = 5
neurons) (from reference 31).
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type selective, since other NMDA receptor subunits
such as NR1 and NR2A did not show any significant
change (Figure 5). The increased NR2B receptors are
likely to be within synapses, because single-shock focal
stimulation induced NR2B receptor-mediated synaptic
currents were enhanced. Furthermore, a recent study
reported that gentiopicroside, an analgesic compound
for inflammatory pain, reduced the expression of ACC
NR2B induced by the injury, as well as NMDA receptor
mediated responses [45].
In an animal model of arthritic pain, it has been
reported that inflammation increased phosphorylation
but not up-regulation of NMDA NR1 proteins in the
central amygdale [46]. In parallel, NMDA receptor
mediated responses are also enhanced.
Sensitivity to inhibition by protein kinase M zeta (PKMζ)
inhibitor ZIP
What is likely to be the synaptic mechanism responsible
for the analgesic effects produced by ZIP in neuropathic
pain? PKMζ can potentiate postsynaptically the ampli-
tude of AMPA receptor-mediated EPSCs [37,47].
Because glutamatergic synaptic transmission in the ACC
is increased after nerve injury [36], we speculated that
PKMζ may contribute to the maintenance of enhanced
synaptic transmission induced by nerve injury. First, we
recorded AMPA receptor-mediated EPSCs in layer II/III
of the ACC 3 or 7 days after nerve injury [37]. We
found that bath application of ZIP (5 μM) significantly
reduced eEPSCs (Figure 6). In contrast, ZIP did not
affect the amplitude of eEPSCs recorded in neurons
from sham-operated mice.
5. Biochemical markers
Membrane GluR1 expression
The trafficking of AMPA receptor subunits has been
proposed to contribute to synaptic plasticity underlying
hyperalgesia [48-50]. We investigated the distribution of
AMPA receptor subunits in the ACC after nerve liga-
tion. We found that induction of neuropathic pain by
Figure 5 Increased NMDA NR2B receptor-mediated postsynaptic currents in adult ACC neurons is shown after inflammation.A ,
Confocal image of a pyramidal neuron in an adult ACC slice loaded with Lucifer yellow (top left). The arrow indicates the location of the neuron
in the ACC slice (bottom left). Scale bar, 20 μm. When injected with current steps from -100 to 100 pA in 400 ms (bottom right), the neuron
shown at the left fired repetitive action potentials with frequency adaptation (top right). A minority of neurons recorded (n = 4) showed the
fast-spike properties (middle right). B, Current-voltage plot of the NMDA receptor EPSCs. The currents exhibited strong outward rectification and
the reversal potential of the linear part was 4.4 ± 2.0 mV (n = 6 neurons/5 mice). Inset, NMDA receptor-mediated EPSCs recorded at holding
potentials from -65 to 50 mV. Each trace represents the average of five consecutive recordings. C, A selective NR2B antagonist, Ro 25-6981,
partially inhibited NMDA receptor-mediated EPSCs. The time course of changes in EPSC amplitude before and during the application of Ro 25-
6981 (0.3 and 3 μM) and AP-5 (50 μM) in ACC neurons from both saline (control, Δ) and CFA-injected () mice is shown. Traces show the currents
at different time points during application of drugs. Ro 25-6981 produced its maximal effect at 3 min after bath application, and a higher dose
of Ro 25-6981 (3 μM) had no additional effects. The remaining currents can be totally blocked by AP-5 (50 μM). D, Summary data of the effects
Ro 25-6981 (0.3 and 3 μM) in ACC neurons of control (saline-injected) and CFA-injected mice. Ro 25-6981 produced significantly greater
inhibitory effects on NMDA receptor-mediated EPSCs in ACC neurons in CFA-injected mice (n = 9 neurons/8 mice) than those in control adult
mice (n = 8 neurons/7 mice). AP-5 (50 μM) completely blocked the currents, confirming the currents are mediated NMDA receptors (n = 5
slices/5 mice). The double asterisks indicate significant difference from control, and the double daggers indicate significant difference from
control NMDA receptor-mediated EPSCs. Error bars represent SEM (from Reference 24).
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abundance of the GluR1 subunits in the membrane frac-
tion and a corresponding decrease in the levels in the
cytosolic fraction. In contrast, nerve ligation had no
effect on the intracellular distribution of GluR2/3 subu-
nits in ACC neurons [36]. The data show that AMPA
receptor GluR1 subunit is redistributed in ACC neurons
as a result of nerve injury.
In rats with CFA inflammation, Bie et al reported that
AMPA GluR1 in the synapsome preparation of the ACC
neurons from rats with CFA injection showed significant
increases, suggesting that synaptic AMPA GluR1 is sig-
nificantly increased [35].
Phosphorylation of GluR1
The phosphorylation of GluR1 subunit of AMPA recep-
tors is critical for synaptic expression of the receptors,
their channel properties, and synaptic plasticity [51-53].
We tested the phosphorylation levels of GluR1 subunit
at the PKA phosphorylation site (Ser 845) in the ACC
of the mice with nerve ligation. We found that the
phosphorylation levels of GluR1 were significantly
increased in the ACC after nerve injury. The data indi-
cate that the nerve injury can increase the phosphoryla-
tion levels of GluR1 through the PKA signaling pathway.
Upregulation of PKMζ as an marker
We examined whether, in the ACC, peripheral nerve
injury causes changes in PKMζ [37]. Behavioral allodynic
response was increased 3 days after nerve injury when
compared with the response in sham-treated mice. The
levels of PKMζ in the ACC were significantly increased
after nerve injury. Because PKMζ is activated by phos-
phorylation, we also conducted experiments to detect
possible changes in the level of phosphorylated PKMζ (p-
PKMζ). Consistently, the level of p-PKMζ was also signif-
icantly increased. These data suggest that peripheral
nerve injury increases PKMζ activity in the ACC. To
determine whether such changes are long-lasting, we
examined PKMζ and p-PKMζ levels 7 and 14 days after
nerve injury. Although behavioral allodynia persisted at
these time points, the protein levels of PKMζ returned to
baseline (Figure 7), indicating that the regulation of the
amount of PKMζ is short-lasting. However, the p-PKMζ
Figure 6 Inhibition of PKMζ selectively decreased the amplitude of eEPSCs in ACC neurons of mice with neuropathic pain by reducing
the number of active AMPA receptors. A and B, Samples showed the effect of ZIP (5 μM) on the amplitude of eEPSCs in the ACC neurons of
animals from the nerve injury [black circles in (A)] and sham group [black circles in (B)]. The gray open circles represent the change of
membrane resistance during recording. Black traces in the upper part of (A) and (B) indicate the averaged response at baseline, and blue traces
indicate the average of 2 min responses collected 10 min after ZIP application. C, Pooled data of effects of ZIP on the eEPSCs recorded from the
ACC of mice in the sham (open) and nerve injury (solid) groups 10 min after ZIP application. *P < 0.05; error bars, SEMs (from Reference 32).
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Page 9 of 14level remained increased, suggesting that PKMζ activity
could contribute to the maintenance of neuropathic pain.
To investigate whether the changes in PKMζ protein
levels or activity were a generalized phenomenon in the
central nervous system, we also examined the levels of
PKMζ and p-PKMζ in the hippocampus and spinal dorsal
horn 3 days after nerve injury.
6. In vivo electrophysiological as direct evidence for
chronic pain
In brain slices, cingulate synapses can undergo LTP after
experimentally designed training protocols. One key
question regarding ACC plasticity is whether or not
injury causes long-term changes in synaptic transmis-
sion in the ACC in intact animals. To test this, we per-
formed experiments in anesthetized rats. We measured
synaptic responses to peripheral electrical shocks by pla-
cing a recording electrode in the ACC of anesthetized
rats [54]. At high intensities of stimulation, sufficient to
activate nociceptive Aδ and C fibers, evoked field EPSPs
were recorded in the ACC. Digit amputation at the con-
tralateral hindpaw causes a rapid and long-lasting
enhancement (more than 120 min) of sensory responses
(Figure 8). Potentiated sensory responses do not require
Figure 7 Expression and phosphorylation of PKMζ in the ACC during neuropathic pain. A, Mechanical allodynia was tested in the sham
and nerve injury groups from wild-type (WT) and AC1
-/- animals 3 days after nerve injury. * indicates P < 0.05; error bars indicate SEMs. B,
Western blots for PKMζ and p-PKMζ in the ACC obtained between 3 days and 2 weeks after nerve injury. (The ACC of mice from the sham and
nerve injury groups were used for Western blot analysis 90 min after the allodynia test.) C, Level of PKMζ in the ACC of mice from the sham and
nerve injury groups. Level of PKMζ increased significantly 3 days after nerve injury compared with PKMζ in the sham group. D, Level of p-PKMζ
increased significantly 3 days after nerve injury. This effect lasted over 2 weeks after nerve injury compared with p-PKMζ in the sham group
(from Reference 32).
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Page 10 of 14persistent activity from the injured hindpaw [54]. These
findings indicate that plastic changes are likely occurring
within the ACC synapses. Furthermore, in vivo intracel-
lular recordings from anesthetized rats have confirmed
similar findings [55].
7. Long-term structural changes
It has been known that learning related plasticity
requires transcriptional and translational processing and
triggers long-term structural changes in individual
synapses [56]. Considering wide-spreading neuronal
plasticity happens in the central nervous system after a
p e r i p h e r a li n j u r y ,i ti se x p e c t e dt of i n dl o n g - t e r m
changes in brain areas related to chronic pain. The well
known cortical reorganization of somatosensory cortex
was reported in monkeys with amputated arms.
Recently, in patients with chronic pain such as chronic
back pain, loss of cortical areas has been reported [7,57].
In animal models of inflammatory pain or chronic pain,
it has been reported that inhibiting macromolecular synth-
esis is analgesic [58]. Structural or synaptic changes after
nerve injury have also been reported in cortical areas
[59,60]. Metz et al reported that layer 2/3 pyramidal neu-
rons in acute slices of the contralateral medial prefrontal
cortex (mPFC) in the rat spared nerve injury model of
neuropathic pain showed morphological differences
between the mPFC of injured and sham-operated animals
[60]. Basal dendrites of neurons from injured rats are
longer and have more branches than their counterparts in
sham-operated animals; spine density is also selectively
increased in basal dendrites of neurons from injured rats.
8. Imaging ACC activity and spike recording in
experimental animals
Electrophysiological recordings of sensory induced unit
responses from cortical neurons is another direct mea-
sure of injury induced cortical changes. The use of
responsive threshold, the measurement of receptive field,
and changes in the magnitude of nociceptive responses
are good indexes for injury related cortical plasticity. It is
likely that heterogeneous populations of cells are likely
found. For example, in the amygdala, Neugebauer and Li
reported (2002) that amygdala neurons showed differen-
tial sensitization (measured by spike activities) to sensory
afferent inputs in a model of arthritic pain [61].
In addition to spike recordings, recent studies using
whole-cell patch-clamp recordings from adult ACC neu-
rons found that many of ACC neurons are responsive to
peripheral nociceptive stimulation. Whole-cell patch-
clamp recording offer better sensitivity for detecting
possible changes in chronic pain, and evaluate the possi-
ble analgesic effects of drugs [62].
Recent several studies have reported brain activation
in awake rats using the imaging technique [63]. In this
novel approach, Becerra et al (2010) performed fMRI in
trained, acclimated, awake rats [63]. The new approach
avoids the potential complicating effects of anesthesia.
Differing from experiments in humans, animal needs to
be kept under anesthesia state to avoid the movement.
Among many cortical areas, they reported that ACC,
Figure 8 Sensory response of the anterior cingulate cortex to
peripheral stimulation in adult rats. A-B, diagram of in vivo
recording from the anterior cingulate cortex (ACC) in an
anaesthetized rat; animals were maintained in a lightly
anaesthetized state by halothane. The recording electrode was
placed into the ACC contralateral to the peripheral stimulation
electrode. Amputation (the removal of the third digit of the
hindpaw) was performed on the non-stimulated hindpaw. During
amputation, a higher concentration of halothane was used. C, Long-
lasting enhancement following amputation of a single hindpaw
digit A, representative traces of EPSPs 5 min before amputation
(Pre) and 115-120 min after (Post) sham treatment or amputation.
The he latency of sensory responses was not changed after the
amputation, while the EPSP slope was increased. D, amputation of a
single digit of the contralateral hindpaw (indicated by an arrow)
caused long-lasting enhancement of sensory responses (￿). Sensory
responses were not significantly changed in sham-treated animals
(○). The test stimulation frequency was 0.01 Hz (from Reference 54).
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approach can be effectively used for evaluating effects of
new drugs on pain in awake animals.
Examples how cortical endpoints can be used
It is known that injury triggers molecular and cellular
changes in different parts of the brains. Depending on
the specific regions of the brain, these neurobiological
changes may contribute to different aspects of pain,
such as learning and memory, anxiety, unpleasantness
and attention. Although some of these changes can be
observed at behavioral levels (i.e., reduced latency to
withdrawal; or enhanced responses to noxious stimuli),
some are difficult to be studied at behavioral level. One
good example to use the cortical endpoints is to evalu-
ate the effects of new drugs in spinal cord injury
induced pain. It is commonly reported in patients with
spinal cord injury that they suffer long-lasting neuro-
pathic pain caused by the injury. However, in animal
models of spinal cord injury, it is impossible to evaluate
the drug’s analgesic effect using behavioral tests. Using
the proposed cortical endpoints, I propose that these
cortical endpoints can be used. For example, activation
of various IEGs in the pain-related cortex such as ACC
can be used to evaluate early activation, and measuring
glutamate mediated responses and biochemical markers
can be used to evaluate enhanced transmission during
chronic pain induced by spinal cord injury. The drugs
that inhibited or erased cortical makers may be poten-
tially useful for treating spinal cord injury related
chronic pain in patients.
The same endpoints can be used to evaluate drugs that
acting at peripheral or spinal mechanisms. In additional
behavioral responses, cortical endpoints can be measured
before and after drug application. Drugs that reduce per-
ipheral or spinal sensitization or potentiation should
reduce activation of cortical markers. The cortical mea-
surement will help to determine if behavioral inhibition
is due to pure inhibition of motor neurons that are
required for sensitized withdrawal responses in chronic
pain conditions. There are some limitations of using
these proposed cortical indexes to study ‘pain’ in animals.
It is important to perform additional experiments to dis-
tinguish possible changes in these cortical indexes that
are important for pain-related memory but not pain
itself. Considering that cortical neurons are often acti-
vated in different situations, it is not an easy task if the
injury is also located within the brain. The use of selec-
tive gene-manipulated mice or pharmacological inhibi-
tors may help to address some of these concerns.
Conclusion
In summary, recent basic neurobiological investigations
of physiological and pathological mechanisms of pain
and chronic pain provide critical information for our
understanding of long-term plastic changes in cortical
areas. These cortical changes that persisted during the
course of chronic pain can be used a valuable index to
measure ‘pain’ in animals. The combined use of these
neurobiological indexes, together with or without beha-
vioral motor withdrawal responses, will greatly facilitate
our searching for new drugs, and also help us to under-
stand why some of current pain medicine does not work
in some clinical conditions.
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